Oppositional defiant disorder is a childhood-onset disruptive behavior disorder characterized by persistent angry or irritable mood, argumentative or defiant behavior, and vindictiveness that causes impairment.
Ask a research question about Oppositional Defiant Disorder. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).
Do not include personal health information in your question. Questions and results are cached in your browser's local storage.
Conditions with similar clinical presentations that must be differentiated from Oppositional Defiant Disorder:
name: Oppositional Defiant Disorder
creation_date: "2026-04-24T20:56:38Z"
updated_date: "2026-05-03T05:02:39Z"
category: Psychiatric
description: >-
Oppositional defiant disorder is a childhood-onset disruptive behavior
disorder characterized by persistent angry or irritable mood, argumentative
or defiant behavior, and vindictiveness that causes impairment.
disease_term:
preferred_term: oppositional defiant disorder
term:
id: MONDO:0000495
label: oppositional defiant disorder
parents:
- Mental Health Disorder
prevalence:
- population: Spanish general-population children ages 3 to 9
percentage: 21.9
notes: >-
Cumulative risk of new ODD cases up to age 9 in a longitudinal cohort;
this is an incidence-risk estimate rather than point prevalence.
evidence:
- reference: DOI:10.1136/bmjopen-2018-022493
reference_title: "First incidence, age of onset outcomes and risk factors of onset of DSM-5 oppositional defiant disorder: a cohort study of Spanish children from ages 3 to 9"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Up to 9 years old, the cumulative risk of new cases of ODD was 21.9%.
explanation: >-
The longitudinal cohort quantifies cumulative onset risk through age 9.
- population: European children and adolescents (community studies 2015-2020)
percentage: 1.9
notes: >-
Pooled prevalence from systematic review and meta-analysis of community
studies across Europe.
evidence:
- reference: PMID:36581685
reference_title: "A systematic review and meta-analysis on the prevalence of mental disorders among children and adolescents in Europe."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
ODD (1.9% (95% CI 1.0-3.7%, I2 = 98.4%))
explanation: >-
Meta-analysis of European community studies provides pooled ODD
prevalence of 1.9%.
- population: Middle childhood, non-referred children (meta-analysis)
notes: >-
ODD prevalence is significantly higher in boys than girls with a
male-to-female ratio of 1.59:1 (N = 44,107).
evidence:
- reference: PMID:27282758
reference_title: "Sex Differences in the Prevalence of Oppositional Defiant Disorder During Middle Childhood: a Meta-Analysis."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
the prevalence of ODD was significantly higher in boys
explanation: >-
Meta-analysis of 19 studies (N = 44,107) establishes male preponderance
in ODD prevalence during middle childhood.
- population: Chinese school children and adolescents ages 6 to 16
notes: >-
ODD was among the disorders with highest rates of comorbidity in a
national-scale epidemiological survey of 73,992 children.
evidence:
- reference: PMID:34019305
reference_title: "Prevalence of mental disorders in school children and adolescents in China: diagnostic data from detailed clinical assessments of 17,524 individuals."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Individuals diagnosed with attention-deficit hyperactivity disorder,
oppositional defiant disorder, a tic disorder, conduct disorder, and
major depression disorder had the highest rates of comorbidity
explanation: >-
Large-scale Chinese epidemiological survey identifies ODD as among
the most comorbid childhood psychiatric disorders.
pathophysiology:
- name: Developmental Familial and Temperamental Risk
description: >-
ODD risk is modeled as emerging from early childhood temperament,
inhibitory and emotional-control difficulties, ADHD/comorbidity burden, and
family-context risk factors.
downstream:
- target: Prenatal Exposure and DNA Methylation Associations
description: >-
Maternal internalizing problems and prenatal exposures are modeled as
developmental risk inputs that may leave methylation signatures.
- target: Emotion and Executive-Control Dysregulation
description: >-
Negative affectivity and poor inhibitory/emotional control are modeled
upstream of emotion and executive-control impairment.
evidence:
- reference: DOI:10.1136/bmjopen-2018-022493
reference_title: "First incidence, age of onset outcomes and risk factors of onset of DSM-5 oppositional defiant disorder: a cohort study of Spanish children from ages 3 to 9"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Subthreshold ODD, high scores in irritability and headstrong dimensions,
attention deficit/hyperactivity disorder and other comorbidity, negative
affectivity until age 7, difficulties in inhibit and emotional control,
punitive parenting and maternal internalising problems were risk factors
of a first episode of ODD during this 7-year period.
explanation: >-
Prospective cohort evidence supports multifactorial developmental and
family-context risk.
- name: Prenatal Exposure and DNA Methylation Associations
description: >-
Birth DNA methylation patterns associated with later ODD trajectories
suggest developmental embedding of prenatal exposures and partial genetic
influence on methylation.
biological_processes:
- preferred_term: response to stress
term:
id: GO:0006950
label: response to stress
modifier: ABNORMAL
downstream:
- target: Neurodevelopmental Pathway Enrichment
description: >-
Epigenetic and genetic findings are modeled upstream of altered
neurodevelopmental pathway vulnerability.
evidence:
- reference: DOI:10.1111/cdev.12957
reference_title: A Methylome-Wide Association Study of Trajectories of Oppositional Defiant Behaviors and Biological Overlap With Attention Deficit Hyperactivity Disorder
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
In 671 mother–child (49% male) pairs from an epidemiological birth
cohort, we investigated (a) prospective associations between DNA
methylation (at birth) and trajectories (ages 7–13) of oppositional
defiant disorder (ODD), and the ODD subdimensions of irritable and
headstrong
explanation: >-
Birth-cohort methylation data support a prenatal molecular association
with later ODD trajectories.
- reference: DOI:10.1111/cdev.12957
reference_title: A Methylome-Wide Association Study of Trajectories of Oppositional Defiant Behaviors and Biological Overlap With Attention Deficit Hyperactivity Disorder
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
DNA methylation associated with prenatal risk exposures of maternal
anxiety (headstrong) and cigarette smoking (ODD and headstrong).
explanation: >-
This supports prenatal exposure associations with ODD-related methylation
signatures.
- name: Neurodevelopmental Pathway Enrichment
description: >-
Genetic analyses in ADHD-associated ODD dimensions did not identify single
genome-wide significant ODD loci, but top-ranked genes converged on
beta-catenin signaling and neurite-outgrowth biology.
biological_processes:
- preferred_term: regulation of nervous system process
term:
id: GO:0031644
label: regulation of nervous system process
modifier: ABNORMAL
cell_types:
- preferred_term: neuron
term:
id: CL:0000540
label: neuron
downstream:
- target: Emotion and Executive-Control Dysregulation
description: >-
Neurodevelopmental pathway vulnerability is represented upstream of
abnormal emotion processing, learning, and executive-control functions.
evidence:
- reference: DOI:10.1002/ajmg.b.32346
reference_title: Gene‐set and multivariate genome‐wide association analysis of oppositional defiant behavior subtypes in attention‐deficit/hyperactivity disorder
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
the proteins encoded by 28 of the 53 top‐ranked genes functionally
interact in a molecular landscape centered around Beta‐catenin signaling
and involved in the regulation of neurite outgrowth.
explanation: >-
GWAS/gene-set analysis supports a neurodevelopmental pathway node.
- name: Emotion and Executive-Control Dysregulation
description: >-
ODD heterogeneity includes impairments in negative emotionality, emotional
self-control, executive functioning, and anxiety/conduct-problem profiles
that relate to functioning and treatment outcomes.
biological_processes:
- preferred_term: cognition
term:
id: GO:0050890
label: cognition
modifier: ABNORMAL
- preferred_term: behavior
term:
id: GO:0007610
label: behavior
modifier: ABNORMAL
downstream:
- target: Irritability
description: >-
Emotion dysregulation is represented as a proximal contributor to
irritable mood symptoms.
- target: Atypical Defiant Behavior
description: >-
Executive-control and emotion-regulation impairments are represented as
proximal contributors to defiant and disruptive behavior.
evidence:
- reference: DOI:10.3390/ijerph20043405
reference_title: "Co-Occurring Conduct Problems and Anxiety: Implications for the Functioning and Treatment of Youth with Oppositional Defiant Disorder"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The Moderate Anxiety/High Conduct Problems group exhibited more severe
behavioral problems, greater difficulties with negative emotionality,
emotional self-control, and executive functioning
explanation: >-
Clinical subgroup analysis supports emotion-control and executive
dysfunction as mechanistic dimensions.
- reference: PMID:31301625
reference_title: "Sympathetic arousal in children with oppositional defiant disorder and its relation to emotional dysregulation."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
children with ODD+CBCL-DP presented higher levels of sympathetic
arousal for anger and sadness stimuli compared to the other two groups
explanation: >-
Electrodermal activity data show heightened sympathetic arousal for
negative emotions in ODD children with dysregulation profiles.
- name: Family Interaction and Treatment-Responsive Behavior Cycles
description: >-
Parent training and parent-management interventions target family
interaction patterns and improve ODD/disruptive behavior symptoms,
supporting family-context mechanisms as modifiable downstream contributors.
biological_processes:
- preferred_term: social behavior
term:
id: GO:0035176
label: social behavior
modifier: ABNORMAL
downstream:
- target: Atypical Defiant Behavior
description: >-
Family interaction patterns are represented as modifiable contributors to
observed disruptive and defiant behavior.
evidence:
- reference: DOI:10.3389/fpsyg.2024.1293244
reference_title: "Parent training for disruptive behavior symptoms in attention deficit hyperactivity disorder: a randomized clinical trial"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Parent training was effective in reducing symptoms of ADHD (p = 0.030)
and ODD (p = 0.026) irrespective of modality (p = 1.000).
explanation: >-
Randomized clinical trial supports parent training as an intervention on
ODD symptoms.
- reference: DOI:10.1007/s10578-021-01306-3
reference_title: "Parent Management Training Combined with Group-CBT Compared to Parent Management Training Only for Oppositional Defiant Disorder Symptoms: 2-Year Follow-Up of a Randomized Controlled Trial"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Results showed long-term effectiveness of both PMT and PMT combined with
CPP in reduced disruptive behavior problems and harsh parenting
strategies, and increased emotion regulation- and social communication
skills.
explanation: >-
Long-term RCT follow-up supports parent-management treatment effects on
disruptive behavior and emotion/social communication skills.
phenotypes:
- name: Atypical Defiant Behavior
category: Behavioral
description: >-
Persistent argumentative, defiant, and disruptive behavior is the core ODD
behavioral presentation.
phenotype_term:
preferred_term: Oppositional and defiant behavior
term:
id: HP:0000708
label: Atypical behavior
evidence:
- reference: DOI:10.1136/bmjopen-2018-022493
reference_title: "First incidence, age of onset outcomes and risk factors of onset of DSM-5 oppositional defiant disorder: a cohort study of Spanish children from ages 3 to 9"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
the parent-rated Strengths and Difficulties Questionnaire conduct
problems scale plus ODD Diagnostic and Statistical Manual of Mental
Disorders, fourth version, symptoms were used to screen for behavioural
problems.
explanation: >-
Cohort screening used behavioral-problem and ODD symptom measures.
- reference: PMID:25886655
reference_title: "The pharmacological management of oppositional behaviour, conduct problems, and aggression in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, and conduct disorder: a systematic review and meta-analysis."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Children with attention-deficit hyperactivity disorder (ADHD) may have
oppositional behaviour, conduct problems, and aggression
explanation: >-
Systematic review identifies oppositional behaviour as a recognized
symptom domain in youth with ODD.
- name: Irritability
category: Behavioral
description: Angry and irritable mood is a major ODD symptom dimension.
phenotype_term:
preferred_term: Irritability
term:
id: HP:0000737
label: Irritability
evidence:
- reference: DOI:10.1136/bmjopen-2018-022493
reference_title: "First incidence, age of onset outcomes and risk factors of onset of DSM-5 oppositional defiant disorder: a cohort study of Spanish children from ages 3 to 9"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Subthreshold ODD, high scores in irritability and headstrong dimensions,
attention deficit/hyperactivity disorder and other comorbidity
explanation: >-
Prospective cohort identified irritability and headstrong dimensions as
ODD onset risk factors.
- reference: PMID:31301625
reference_title: "Sympathetic arousal in children with oppositional defiant disorder and its relation to emotional dysregulation."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Emotional dysregulation (ED) is a trans-nosographical condition
characterized by mood instability, severe irritability, aggression,
temper outburst, and hyper-arousal
explanation: >-
ODD-focused study characterizes emotional dysregulation including
severe irritability as a core feature.
- name: Aggressive Behavior
category: Behavioral
description: >-
Aggressive behavior may occur as an externalizing outcome or comorbid
conduct-problem feature in ODD populations.
phenotype_term:
preferred_term: Aggressive behavior
term:
id: HP:0000718
label: Aggressive behavior
evidence:
- reference: DOI:10.1002/ajmg.b.32346
reference_title: Gene‐set and multivariate genome‐wide association analysis of oppositional defiant behavior subtypes in attention‐deficit/hyperactivity disorder
supports: PARTIAL
evidence_source: HUMAN_CLINICAL
snippet: >-
ODD is also a common antecedent to both affective disorders and
aggressive behaviors.
explanation: >-
Genetic study abstract links ODD with later aggressive behaviors.
- reference: PMID:25886655
reference_title: "The pharmacological management of oppositional behaviour, conduct problems, and aggression in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, and conduct disorder: a systematic review and meta-analysis."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
There is high-quality evidence that psychostimulants have a
moderate-to-large effect on oppositional behaviour, conduct problems,
and aggression in youth with ADHD, with and without ODD or CD
explanation: >-
Meta-analysis confirms aggression as a recognized symptom domain in
youth with ODD.
- name: Anxiety
category: Behavioral
description: Anxiety symptoms commonly co-occur in youth with ODD.
phenotype_term:
preferred_term: Anxiety
term:
id: HP:0000739
label: Anxiety
evidence:
- reference: DOI:10.3390/ijerph20043405
reference_title: "Co-Occurring Conduct Problems and Anxiety: Implications for the Functioning and Treatment of Youth with Oppositional Defiant Disorder"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Conduct problems and anxiety symptoms commonly co-occur among youths with
oppositional defiant disorder (ODD)
explanation: >-
Clinical sample study supports anxiety as a common co-occurring symptom
domain.
- name: Emotional Lability
category: Behavioral
description: >-
Emotional lability and mood instability, including temper outbursts and
rapid shifts between anger and sadness, are prominent features in ODD
with emotional dysregulation.
phenotype_term:
preferred_term: Emotional lability
term:
id: HP:0000712
label: Emotional lability
evidence:
- reference: PMID:31301625
reference_title: "Sympathetic arousal in children with oppositional defiant disorder and its relation to emotional dysregulation."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Emotional dysregulation (ED) is a trans-nosographical condition
characterized by mood instability, severe irritability, aggression,
temper outburst, and hyper-arousal
explanation: >-
Study characterizes mood instability and temper outbursts as core
features of emotional dysregulation in ODD.
- name: Sleep Disturbance
category: Behavioral
description: >-
Sleep problems bidirectionally predict and are predicted by ODD in
longitudinal analyses. Restless sleep and difficulty falling asleep are
the most common sleep symptoms.
phenotype_term:
preferred_term: Sleep disturbance
term:
id: HP:0002360
label: Sleep disturbance
evidence:
- reference: PMID:24745954
reference_title: "Sleep problems predict and are predicted by generalized anxiety/depression and oppositional defiant disorder."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
sleep problems predicted increases in the prevalence of later
generalized anxiety disorder (GAD) and high GAD/depression symptoms,
and oppositional defiant disorder (ODD). In turn, GAD and/or depression
and ODD predicted increases in sleep problems over time
explanation: >-
Longitudinal population sample demonstrates bidirectional prediction
between sleep problems and ODD.
- reference: PMID:24745954
reference_title: "Sleep problems predict and are predicted by generalized anxiety/depression and oppositional defiant disorder."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Sleep problems during childhood and adolescence were common, with
restless sleep and difficulty falling asleep being the most common
symptoms
explanation: >-
The same study identifies specific sleep problem types most commonly
associated with ODD.
- name: Impulsivity
category: Behavioral
description: >-
Impulsivity is a feature commonly associated with ODD, particularly in the
context of comorbid ADHD. Impulsive behavior contributes to the headstrong
symptom dimension.
phenotype_term:
preferred_term: Impulsivity
term:
id: HP:0100710
label: Impulsivity
evidence:
- reference: DOI:10.1136/bmjopen-2018-022493
reference_title: "First incidence, age of onset outcomes and risk factors of onset of DSM-5 oppositional defiant disorder: a cohort study of Spanish children from ages 3 to 9"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
difficulties in inhibit and emotional control
explanation: >-
Inhibitory control difficulties (a core component of impulsivity) are
identified as risk factors for ODD onset.
diagnosis:
- name: Clinical disruptive-behavior assessment
presence: >-
Diagnosis is clinical and based on persistent ODD symptoms, impairment,
duration, settings affected, developmental context, and comorbidity
assessment.
diagnosis_term:
preferred_term: clinical assessment
term:
id: MAXO:0000487
label: clinical assessment
evidence:
- reference: DOI:10.1136/bmjopen-2018-022493
reference_title: "First incidence, age of onset outcomes and risk factors of onset of DSM-5 oppositional defiant disorder: a cohort study of Spanish children from ages 3 to 9"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
the parent-rated Strengths and Difficulties Questionnaire conduct
problems scale plus ODD Diagnostic and Statistical Manual of Mental
Disorders, fourth version, symptoms were used to screen for behavioural
problems.
explanation: >-
Cohort methodology supports rating-scale screening followed by diagnostic
evaluation.
- name: Multi-informant symptom and functioning assessment
presence: >-
Parent, teacher, clinician, and youth reports help assess symptom severity,
impairment, school functioning, anxiety, and conduct-problem profiles.
diagnosis_term:
preferred_term: clinical assessment
term:
id: MAXO:0000487
label: clinical assessment
evidence:
- reference: DOI:10.3390/ijerph20043405
reference_title: "Co-Occurring Conduct Problems and Anxiety: Implications for the Functioning and Treatment of Youth with Oppositional Defiant Disorder"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Differences among the subgroups in clinician-, parent-, and/or
self-reported accounts of symptom severity, school performance,
underlying processing known to be impaired across ODD, conduct and
anxiety disorders, self-concept, and psychosocial treatment outcomes were
examined.
explanation: >-
Clinical subgroup study supports multi-informant symptom and functioning
assessment.
- name: Treatment-response and emotion-regulation assessment
presence: >-
Emotion regulation is assessed as a potential moderator of psychosocial
treatment response in children with ODD.
diagnosis_term:
preferred_term: clinical assessment
term:
id: MAXO:0000487
label: clinical assessment
evidence:
- reference: clinicaltrials:NCT06194994
reference_title: "Emotion Regulation as a Moderator of Two Different Treatments for Children With Oppositional Defiant Disorder: A Randomized Clinical Trial"
supports: SUPPORT
snippet: >-
The goal of this randomized controlled trial is to is to test emotion
regulation as a moderator of two different treatments for children with
Oppositional Defiant Disorder (ODD).
explanation: >-
Trial record documents emotion-regulation assessment as a treatment
moderator.
differential_diagnoses:
- name: Conduct disorder
description: >-
Conduct disorder involves more severe rule-breaking or rights-violating
behavior and often co-occurs with or follows ODD.
disease_term:
preferred_term: conduct disorder
term:
id: MONDO:0005352
label: conduct disorder
evidence:
- reference: DOI:10.3390/ijerph20043405
reference_title: "Co-Occurring Conduct Problems and Anxiety: Implications for the Functioning and Treatment of Youth with Oppositional Defiant Disorder"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Conduct problems and anxiety symptoms commonly co-occur among youths with
oppositional defiant disorder (ODD)
explanation: >-
The study supports conduct-problem assessment in ODD populations.
- name: Attention deficit-hyperactivity disorder
description: >-
ADHD commonly co-occurs with ODD and can drive impairment through
inattention, impulsivity, and hyperactivity that require separate
treatment planning.
notes: >-
ADHD comorbidity is modeled under differential diagnoses because the
current Disease schema has no dedicated comorbidities slot.
disease_term:
preferred_term: attention deficit-hyperactivity disorder
term:
id: MONDO:0007743
label: attention deficit-hyperactivity disorder
evidence:
- reference: PMID:34019305
reference_title: "Prevalence of mental disorders in school children and adolescents in China: diagnostic data from detailed clinical assessments of 17,524 individuals."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Individuals diagnosed with attention-deficit hyperactivity disorder,
oppositional defiant disorder, a tic disorder, conduct disorder, and
major depression disorder had the highest rates of comorbidity
explanation: >-
National epidemiological survey identifies ODD and ADHD as among the
most comorbid childhood disorders.
- reference: PMID:36581685
reference_title: "A systematic review and meta-analysis on the prevalence of mental disorders among children and adolescents in Europe."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
ADHD (2.9% (95% CI 1.2-6.9%, I2 = 94.3%)), ODD (1.9% (95% CI
1.0-3.7%, I2 = 98.4%))
explanation: >-
Meta-analysis reports ADHD and ODD prevalence rates in the same
population, supporting ADHD as an important co-occurring condition.
- reference: DOI:10.3389/fpsyg.2024.1293244
reference_title: "Parent training for disruptive behavior symptoms in attention deficit hyperactivity disorder: a randomized clinical trial"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
BackgroundAttention-Deficit/Hyperactivity Disorder (ADHD) affects 5% of
children and 2.5% of adults worldwide.
explanation: >-
RCT background and study design support ADHD as a major comorbid context
for ODD symptoms.
- name: Intermittent explosive disorder
description: >-
Intermittent explosive disorder can present with episodic aggressive
outbursts, but differs from the persistent angry/defiant pattern of ODD.
disease_term:
preferred_term: intermittent explosive disorder
term:
id: MONDO:0001521
label: intermittent explosive disorder
evidence:
- reference: DOI:10.1002/ajmg.b.32346
reference_title: Gene‐set and multivariate genome‐wide association analysis of oppositional defiant behavior subtypes in attention‐deficit/hyperactivity disorder
supports: PARTIAL
evidence_source: HUMAN_CLINICAL
snippet: >-
ODD is also a common antecedent to both affective disorders and
aggressive behaviors.
explanation: >-
The abstract supports aggressive behaviors as a related clinical domain;
the intermittent explosive disorder distinction is a clinical
differential inference.
treatments:
- name: Parent management training
description: >-
Parent management training and behavioral parent training are core
psychosocial interventions for reducing ODD and disruptive behavior
symptoms.
treatment_term:
preferred_term: parent management training
term:
id: MAXO:0000077
label: behavioral counseling
target_phenotypes:
- preferred_term: Behavioral abnormality
term:
id: HP:0000708
label: Atypical behavior
- preferred_term: Irritability
term:
id: HP:0000737
label: Irritability
evidence:
- reference: DOI:10.3389/fpsyg.2024.1293244
reference_title: "Parent training for disruptive behavior symptoms in attention deficit hyperactivity disorder: a randomized clinical trial"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Parent training was effective in reducing symptoms of ADHD (p = 0.030)
and ODD (p = 0.026) irrespective of modality (p = 1.000).
explanation: >-
Randomized clinical trial evidence supports parent training for ODD
symptom reduction.
- reference: DOI:10.1007/s10578-021-01306-3
reference_title: "Parent Management Training Combined with Group-CBT Compared to Parent Management Training Only for Oppositional Defiant Disorder Symptoms: 2-Year Follow-Up of a Randomized Controlled Trial"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Parent management training (PMT) is recommended treatment for children
with oppositional defiant disorder (ODD) and child-directed cognitive
behavior therapy (CBT) is also recommended for school-aged children.
explanation: >-
RCT follow-up abstract identifies PMT as a recommended treatment for
children with ODD.
- name: Child-directed cognitive behavioral therapy
description: >-
Child-directed CBT can be used for school-aged children with ODD,
including Coping Power Program-style problem-solving and emotion-regulation
components.
treatment_term:
preferred_term: cognitive behavior therapy
term:
id: MAXO:0000883
label: cognitive behavior therapy
target_phenotypes:
- preferred_term: Behavioral abnormality
term:
id: HP:0000708
label: Atypical behavior
- preferred_term: Irritability
term:
id: HP:0000737
label: Irritability
evidence:
- reference: DOI:10.1007/s10578-021-01306-3
reference_title: "Parent Management Training Combined with Group-CBT Compared to Parent Management Training Only for Oppositional Defiant Disorder Symptoms: 2-Year Follow-Up of a Randomized Controlled Trial"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Parent management training (PMT) is recommended treatment for children
with oppositional defiant disorder (ODD) and child-directed cognitive
behavior therapy (CBT) is also recommended for school-aged children.
explanation: >-
RCT follow-up abstract supports child-directed CBT as a recommended ODD
treatment for school-aged children.
- name: Atomoxetine pharmacotherapy for ADHD with comorbid ODD
description: >-
Atomoxetine has been studied as pharmacotherapy in children and adolescents
with ADHD and comorbid ODD; this treatment context targets ADHD with
comorbid oppositional symptoms rather than ODD alone.
context: ADHD with comorbid ODD
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
therapeutic_agent:
- preferred_term: atomoxetine
term:
id: CHEBI:127342
label: atomoxetine
target_phenotypes:
- preferred_term: Attention deficit hyperactivity disorder
term:
id: HP:0007018
label: Attention deficit hyperactivity disorder
evidence:
- reference: clinicaltrials:NCT00406354
reference_title: A Randomized, Double-Blind Comparison of Atomoxetine Versus Placebo in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder and Comorbid Oppositional Defiant Disorder
supports: SUPPORT
snippet: >-
A three-arm, randomized, double-blind, placebo-controlled, Phase 4,
multicenter study to compare the efficacy and safety of atomoxetine
versus placebo in children and adolescents aged 6 through 17 years with
attention-deficit/hyperactivity disorder (ADHD) and comorbid oppositional
defiant disorder (ODD) who are treated as outpatients in Germany.
explanation: >-
ClinicalTrials.gov record supports atomoxetine testing in the
ADHD-with-comorbid-ODD treatment context.
- name: Psychostimulant pharmacotherapy for ADHD with comorbid ODD
description: >-
Psychostimulants are supported by high-quality evidence for reducing
oppositional behaviour, conduct problems, and aggression in youth with
ADHD, with and without comorbid ODD.
context: ADHD with comorbid ODD
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
therapeutic_agent:
- preferred_term: psychostimulant
term:
id: NCIT:C47795
label: CNS Stimulant
target_phenotypes:
- preferred_term: Aggressive behavior
term:
id: HP:0000718
label: Aggressive behavior
- preferred_term: Behavioral abnormality
term:
id: HP:0000708
label: Atypical behavior
evidence:
- reference: PMID:25886655
reference_title: "The pharmacological management of oppositional behaviour, conduct problems, and aggression in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, and conduct disorder: a systematic review and meta-analysis."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
There is high-quality evidence that psychostimulants have a
moderate-to-large effect on oppositional behaviour, conduct problems,
and aggression in youth with ADHD, with and without ODD or CD
explanation: >-
Systematic review and meta-analysis provides high-quality evidence for
psychostimulant efficacy on ODD symptoms.
- reference: PMID:25886655
reference_title: "The pharmacological management of oppositional behaviour, conduct problems, and aggression in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, and conduct disorder: a systematic review and meta-analysis."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
psychostimulants generally provide the most benefit
explanation: >-
Meta-analysis concludes psychostimulants provide the most benefit
among ADHD medications for oppositional and aggressive behaviours.
clinical_trials:
- name: NCT06194994
phase: NOT_APPLICABLE
status: RECRUITING
description: >-
Randomized clinical trial testing whether emotion regulation moderates
response to behavioral parent training versus child-directed
problem-solving and emotion-regulation treatment.
target_phenotypes:
- preferred_term: Irritability
term:
id: HP:0000737
label: Irritability
evidence:
- reference: clinicaltrials:NCT06194994
reference_title: "Emotion Regulation as a Moderator of Two Different Treatments for Children With Oppositional Defiant Disorder: A Randomized Clinical Trial"
supports: SUPPORT
snippet: >-
Participants will be divided into two groups based on their response
patterns; a high emotion dysregulation group and a low emotion
dysregulation group.
explanation: >-
ClinicalTrials.gov record documents emotion regulation as the moderator
under study.
- name: NCT06410495
phase: NOT_APPLICABLE
status: RECRUITING
description: >-
Pilot web-based dyadic CBT-I intervention adapted for children with ODD and
their parents.
target_phenotypes:
- preferred_term: Behavioral abnormality
term:
id: HP:0000708
label: Atypical behavior
evidence:
- reference: clinicaltrials:NCT06410495
reference_title: "Digital Dyadic Family Based Intervention to Improve Sleep in Children with ODD and Their Parents: NiteCAPP SINCC (Pilot)"
supports: SUPPORT
snippet: >-
In this proposal a brief web-based cognitive behavioral treatment for
insomnia (CBT-I) for children with oppositional defiant disorder (ODD)
and their parents is iteratively adapted and tested for acceptability,
feasibility, and preliminary efficacy.
explanation: >-
ClinicalTrials.gov record documents a family-based digital intervention
in children with ODD.
- name: NCT00406354
phase: PHASE_IV
status: COMPLETED
description: >-
Randomized double-blind comparison of atomoxetine versus placebo in
children and adolescents with ADHD and comorbid ODD.
target_phenotypes:
- preferred_term: Attention deficit hyperactivity disorder
term:
id: HP:0007018
label: Attention deficit hyperactivity disorder
evidence:
- reference: clinicaltrials:NCT00406354
reference_title: A Randomized, Double-Blind Comparison of Atomoxetine Versus Placebo in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder and Comorbid Oppositional Defiant Disorder
supports: SUPPORT
snippet: >-
A three-arm, randomized, double-blind, placebo-controlled, Phase 4,
multicenter study to compare the efficacy and safety of atomoxetine
versus placebo in children and adolescents aged 6 through 17 years with
attention-deficit/hyperactivity disorder (ADHD) and comorbid oppositional
defiant disorder (ODD) who are treated as outpatients in Germany.
explanation: >-
ClinicalTrials.gov record documents a completed ADHD-plus-ODD medication
trial.
datasets:
- accession: DOI:10.1136/bmjopen-2018-022493
title: "First incidence, age of onset outcomes and risk factors of onset of DSM-5 oppositional defiant disorder: a cohort study of Spanish children from ages 3 to 9"
description: >-
Longitudinal Spanish general-population cohort following children from
preschool through age 9 to estimate ODD onset risk, outcomes, and risk
factors.
organism:
preferred_term: Homo sapiens
term:
id: NCBITaxon:9606
label: Homo sapiens
sample_count: 622
conditions:
- oppositional defiant disorder
- non-ODD controls
publication: DOI:10.1136/bmjopen-2018-022493
evidence:
- reference: DOI:10.1136/bmjopen-2018-022493
reference_title: "First incidence, age of onset outcomes and risk factors of onset of DSM-5 oppositional defiant disorder: a cohort study of Spanish children from ages 3 to 9"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The second phase sample size contained 622 cases at age 3 and, at age 9,
418 remained in the study.
explanation: >-
The abstract describes the cohort size and retention.
findings:
- statement: ODD onset risk peaked at ages 4 and 5, declined by age 7, and increased again by age 9.
evidence:
- reference: DOI:10.1136/bmjopen-2018-022493
reference_title: "First incidence, age of onset outcomes and risk factors of onset of DSM-5 oppositional defiant disorder: a cohort study of Spanish children from ages 3 to 9"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The probability of the onset of ODD showed increasing values at ages 4
(R=2.7%) and 5 years (R=4.4%).
explanation: >-
Captures the age-specific onset-risk pattern.
- accession: DOI:10.1111/cdev.12957
title: A Methylome-Wide Association Study of Trajectories of Oppositional Defiant Behaviors and Biological Overlap With Attention Deficit Hyperactivity Disorder
description: >-
Epidemiological birth-cohort methylome-wide association study linking DNA
methylation at birth with ODD and ODD-subdimension trajectories ages 7 to
13.
organism:
preferred_term: Homo sapiens
term:
id: NCBITaxon:9606
label: Homo sapiens
sample_count: 671
conditions:
- oppositional defiant disorder
- attention deficit hyperactivity disorder
publication: DOI:10.1111/cdev.12957
evidence:
- reference: DOI:10.1111/cdev.12957
reference_title: A Methylome-Wide Association Study of Trajectories of Oppositional Defiant Behaviors and Biological Overlap With Attention Deficit Hyperactivity Disorder
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
In 671 mother–child (49% male) pairs from an epidemiological birth
cohort
explanation: >-
The abstract provides the cohort size and sample type.
findings:
- statement: Methylome-wide significant associations were found for ODD and headstrong trajectories, with overlap between ODD, headstrong, and ADHD.
evidence:
- reference: DOI:10.1111/cdev.12957
reference_title: A Methylome-Wide Association Study of Trajectories of Oppositional Defiant Behaviors and Biological Overlap With Attention Deficit Hyperactivity Disorder
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Methylome-wide significant associations were identified for the ODD and
headstrong, but not for irritable.
explanation: >-
Captures the principal methylome-wide result.
- accession: DOI:10.3390/ijerph20043405
title: "Co-Occurring Conduct Problems and Anxiety: Implications for the Functioning and Treatment of Youth with Oppositional Defiant Disorder"
description: >-
Clinical-sample latent profile analysis of conduct-problem and anxiety
subgroups among youths with ODD and associations with functioning and
psychosocial treatment outcomes.
organism:
preferred_term: Homo sapiens
term:
id: NCBITaxon:9606
label: Homo sapiens
sample_count: 134
conditions:
- oppositional defiant disorder
- conduct problems
- anxiety symptoms
publication: DOI:10.3390/ijerph20043405
evidence:
- reference: DOI:10.3390/ijerph20043405
reference_title: "Co-Occurring Conduct Problems and Anxiety: Implications for the Functioning and Treatment of Youth with Oppositional Defiant Disorder"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
This study examined subtypes based on these co-occurring symptoms in a
clinical sample of 134 youths (Mage = 9.67, 36.6% female, 83.6% white)
with ODD
explanation: >-
The abstract describes the clinical cohort.
findings:
- statement: Four anxiety/conduct profiles were identified, and the moderate-anxiety/high-conduct group had worse behavioral, emotional-control, executive-functioning, and long-term treatment outcomes.
evidence:
- reference: DOI:10.3390/ijerph20043405
reference_title: "Co-Occurring Conduct Problems and Anxiety: Implications for the Functioning and Treatment of Youth with Oppositional Defiant Disorder"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Four distinct profiles were identified: (1) Low Anxiety/Moderate
Conduct Problems (n = 42); (2) High Anxiety/Moderate Conduct Problems
(n = 33); (3) Moderate Anxiety/Moderate Conduct Problems (n = 40); and
(4) Moderate Anxiety/High Conduct Problems (n = 19).
explanation: >-
Captures the subgrouping result used for ODD heterogeneity.
notes: >-
Pathophysiology entries are separated into developmental risk, prenatal
methylation associations, neurodevelopmental pathway enrichment, emotion and
executive-control dysregulation, and family-interaction mechanisms so
downstream causal relationships are explicit.
Oppositional Defiant Disorder (ODD) is a disruptive behavior disorder characterized by a persistent pattern of angry/irritable mood, argumentative/defiant behavior, and vindictiveness that causes distress or impairment. DSM-5-TR conceptualizes ODD symptoms across these three dimensions. (hawes2023oppositionaldefiantdisorder pages 1-6, hawes2023oppositionaldefiantdisorder pages 55-59)
A DSM-5–based diagnostic summary in the retrieved corpus describes ODD as “a pattern of angry/irritable mood, argumentative/defiant behaviour, or vindictiveness lasting ≥ 6 months” with a minimum number of symptoms and impairment, and severity specified by the number of settings affected. (hawes2023oppositionaldefiantdisorder pages 55-59)
Important limitation: The retrieved full texts did not provide explicit ICD-10/ICD-11 alphanumeric code strings, MeSH IDs, or MONDO IDs; the below reflects classification placement and specifier content only.
Common clinical phrasing includes “oppositional-defiant behavior” and “oppositional defiant symptoms.” (NCT06410495 chunk 1, NCT06194994 chunk 1)
This report is based on aggregated disease-level resources (review/primer, meta-analysis), plus human clinical trials/cohorts, and molecular/physiology studies. (hawes2023oppositionaldefiantdisorder pages 1-6, boldrini2023systematicreviewand pages 9-12, ezpeleta2019firstincidenceage pages 1-2, barker2018amethylomewideassociation pages 1-2)
Current synthesis supports ODD as a multifactorial disorder arising from interactions between genetic liability and environmental contexts, with social-relationship mechanisms contributing to symptom maintenance. (hawes2023oppositionaldefiantdisorder pages 1-6)
Twin/family evidence summarized in the 2023 Nature Reviews Disease Primers article indicates moderate-to-high heritability for ODD, with reported ranges 0.34–0.73, and substantial non-shared environmental influence. (hawes2023oppositionaldefiantdisorder pages 6-9)
In a GWAS/candidate-gene study of ODD symptom dimensions in an ADHD clinical sample, the background states that ODD heritability has been estimated around 0.60, while molecular findings were limited (no genome-wide significant hits in that study). (aebi2016gene‐setandmultivariate pages 1-2)
A longitudinal cohort study (ages 3–9) identified risk factors for a first ODD episode including negative affectivity, difficulties in inhibitory and emotional control, punitive parenting, and maternal internalising problems, among others. (ezpeleta2019firstincidenceage pages 1-2)
Explicit protective factors were not enumerated as such in the retrieved excerpts. Indirectly, the treatment literature and longitudinal work imply that early identification, supportive parenting practices, and evidence-based interventions can improve outcomes and may function as protective influences at the population level. (hawes2023oppositionaldefiantdisorder pages 33-36, ezpeleta2019firstincidenceage pages 1-2)
A methylome-wide association study using DNA methylation at birth and trajectories of ODD behaviors (ages 7–13) reported that methylation signatures associated with ODD/headstrong trajectories were linked to prenatal risk exposures (e.g., maternal anxiety; cigarette smoking) and were partly genetically influenced, consistent with developmental embedding of exposures. The abstract states: “DNA methylation associated with prenatal risk exposures of maternal anxiety (headstrong) and cigarette smoking (ODD and headstrong).” (barker2018amethylomewideassociation pages 1-2)
ODD symptom dimensions (DSM-5-TR framing) include: - Angry/irritable mood - Argumentative/defiant behavior - Vindictiveness (hawes2023oppositionaldefiantdisorder pages 1-6, hawes2023oppositionaldefiantdisorder pages 55-59)
DSM-5-TR criteria summarized in the 2023 Primer include 8 symptom items (e.g., temper loss, touchy/easily annoyed, angry/resentful; argues with authority figures; defies/refuses; deliberately annoys; blames others; spiteful/vindictive), with duration ≥6 months and impairment/distress requirements. (hawes2023oppositionaldefiantdisorder pages 55-59, hawes2023oppositionaldefiantdisorder pages 16-19)
ODD can persist into adolescence/adulthood and is associated with adverse outcomes across health, education, employment, and relationships, with heterogeneity (outcomes not inevitable if symptoms desist). (hawes2023oppositionaldefiantdisorder pages 33-36)
A symptom-level impairment study in a clinical ADHD/DBD cohort reported that individual ODD symptoms differ in functional impact; for example, the ODD symptom “Argues with Adults” contributed strongly to explained variance in global functional impairment linked to disruptive symptoms. (hawes2023oppositionaldefiantdisorder pages 6-9)
Note: These are suggested mappings based on the described clinical features; direct HPO database extraction was not performed in-tool. - Irritable mood / anger: HP:0000737 (Irritability) (suggested) - Temper outbursts: HP:0000719 (Aggressive behavior) (suggested) - Defiant/argumentative behavior: HP:0031936 (Oppositional behavior) (suggested; term availability may vary) - Vindictiveness/spitefulness: map to behavioral abnormality terms under Abnormality of behavior (HP:0000708) (suggested) - Executive dysfunction: HP:0031510 (Executive dysfunction) (suggested)
No single causal gene is established for ODD in the retrieved evidence; ODD is best supported as polygenic/multifactorial with shared liability across externalizing phenotypes. (hawes2023oppositionaldefiantdisorder pages 6-9)
A GWAS/candidate-gene study of ODD subdimensions in ADHD evaluated polymorphisms in dopaminergic/serotonergic/oxytocin pathways (including DRD4 exon3 VNTR, 5-HTTLPR, OXTR SNPs) and performed multivariate GWAS, but reported no genome-wide significant loci; top-ranked genes formed an interaction landscape centered on beta-catenin signaling and neurite outgrowth. (aebi2016gene‐setandmultivariate pages 1-2)
A broader GWAS in ADHD with disruptive behavior disorders (including ODD/CD) identified genome-wide significant loci (e.g., rs7118422; OR 1.17), and found higher SNP-heritability for ADHD+DBDs vs ADHD alone (0.34 vs 0.20), with strong genetic correlations with aggression and antisocial behavior (rg ~0.81–0.82). (aebi2016gene‐setandmultivariate pages 1-2)
The methylome-wide study (birth methylation → ODD trajectories) supports epigenetic correlates and prenatal exposure associations (maternal anxiety; cigarette smoking). (barker2018amethylomewideassociation pages 1-2)
Not available / not applicable in retrieved evidence.
The retrieved evidence emphasizes psychosocial and family-system factors rather than toxins/occupational exposures.
A key mechanistic account highlights coercive parent–child cycles maintained by social learning and reinforcement, potentially evolving into maladaptive relational strategies and sustaining oppositional behavior. (hawes2023oppositionaldefiantdisorder pages 55-59)
ODD has been linked to deficits in reinforcement learning, emotion processing, and social cognition, including impaired learning from punishment and difficulties recognizing negative facial expressions (especially anger), and executive function/self-regulation deficits that may persist even without ADHD comorbidity. (hawes2023oppositionaldefiantdisorder pages 12-16)
A neuropsychological case-control study found that visual working memory and inhibitory control were impaired in ODD and CD groups vs controls, and that anger recognition was impaired in ODD; deficits were not explained by ADHD/internalizing comorbidity. (hawes2023oppositionaldefiantdisorder pages 16-19)
The 2023 Primer summarizes structural MRI findings including reduced volumes in orbitofrontal and ventromedial prefrontal regions (some patterns suggested as more ODD-specific) and functional hypo-responsivity across amygdala/insula/OFC/ACC/striatal and other regions involved in emotion recognition/regulation, error processing, and reward learning. (hawes2023oppositionaldefiantdisorder pages 55-59)
The 2023 Primer notes associations between ODD and lower basal cortisol and blunted cortisol responses to psychological stress, and reports that cortisol hyporeactivity predicts weaker response to parent management training in ODD. (hawes2023oppositionaldefiantdisorder pages 12-16)
Mechanisms implicate corticolimbic circuits; cell types are not directly assayed in retrieved evidence. Candidate CL terms for annotation (hypothesis-level): - CL:0000540 (neuron) - CL:0000127 (astrocyte) - CL:0000548 (animal cell) (general)
ODD is primarily a neurobehavioral disorder with correlates in brain systems for emotion regulation, reward/punishment learning, and executive control.
Neuroimaging synthesis implicates: - Amygdala, anterior insula, orbitofrontal cortex, anterior cingulate cortex, striatum, and ventromedial prefrontal regions, among others. (hawes2023oppositionaldefiantdisorder pages 55-59, hawes2023oppositionaldefiantdisorder pages 16-19)
Suggested UBERON terms (examples; suggestions): - UBERON:0000955 (brain) - UBERON:0001873 (amygdala) - UBERON:0000451 (prefrontal cortex) - UBERON:0001882 (striatum)
Representative-sample point prevalence estimates cluster around ~3–5% (meta-analyses summarized in the 2023 Primer: ~3.3% ages 5–18; ~3.9% ages 1–7). Clinical and juvenile-justice samples show substantially higher rates (clinical 28–65%; juvenile justice ~43%). (hawes2023oppositionaldefiantdisorder pages 6-9)
A cumulative lifetime prevalence estimate of ~10.2% is mentioned in the 2023 Primer (noted as variable across samples). (hawes2023oppositionaldefiantdisorder pages 6-9)
A modest male predominance is reported in childhood (~1.6–1.7:1), diminishing by adolescence; adult sex differences may be absent in some samples. (hawes2023oppositionaldefiantdisorder pages 6-9)
ODD shows moderate-to-high heritability and shared genetic liability with externalizing and internalizing phenotypes, loading on a higher-order externalizing genetic factor. (hawes2023oppositionaldefiantdisorder pages 6-9)
DSM-5-TR criteria require ≥4 symptoms (of 8), duration ≥6 months, distress/impairment, and frequency thresholds depending on age (<5 years: most days; ≥5 years: at least once per week). (hawes2023oppositionaldefiantdisorder pages 16-19)
ICD-11 introduces specifiers (LPE; chronic irritability-anger) that reflect heterogeneity and overlap with callous–unemotional traits and chronic irritability phenotypes. (hawes2023oppositionaldefiantdisorder pages 19-22)
The 2023 Primer notes that DSM-IV previously excluded ODD when CD was present, and DSM-5 removed that restriction, affecting prevalence estimation and diagnostic conventions. (hawes2023oppositionaldefiantdisorder pages 6-9)
The 2023 Primer describes a stepped approach: parent/teacher rating scales for screening, followed by more intensive clinical interviews/observations for those screening positive; obtaining multi-informant data is important because cross-setting symptoms indicate severity. Examples include ASEBA and BASC-3 (normed but not DSM-item aligned), SDQ (brief), and DSM-aligned scales like the DBD Rating Scale; parent-rated DBD showed positive predictive power >0.90 for structured interview diagnoses in pediatric samples cited in the Primer. (hawes2023oppositionaldefiantdisorder pages 19-22)
Suggested MAXO terms: - Screening for behavioral disorder: MAXO:0000506 (screening procedure) (suggested) - Structured diagnostic interview: MAXO:0000471 (psychiatric evaluation) (suggested)
ODD is associated with broad impairment and can persist into adulthood, but outcomes are heterogeneous; desistence is associated with better prognosis. (hawes2023oppositionaldefiantdisorder pages 33-36)
A Spanish cohort analysis reported that early onset was associated with markedly higher depression risk; one excerpt notes increased risk of depression “by 5.76” versus children without ODD (as reported in the paper excerpt). (ezpeleta2019firstincidenceage pages 6-7)
Comorbidity profiles may predict worse functioning and poorer long-term treatment outcomes; in a clinical sample, the “Moderate Anxiety/High Conduct Problems” subgroup had worse executive functioning/emotional self-control and worse long-term psychosocial treatment outcomes. (halldorsdottir2023cooccurringconductproblems pages 1-2)
Parenting interventions grounded in social learning principles have the strongest empirical support across childhood and adolescence, with developmental staging enabling increased child participation and teacher/individual components for older youth. (hawes2023oppositionaldefiantdisorder pages 55-59)
A 2-year follow-up RCT comparing PMT vs PMT + group CBT (Coping Power Program) found long-term effectiveness of both arms for reduced disruptive behavior problems and harsh parenting and increased emotion regulation/social communication; combined treatment did not provide broad long-term benefits beyond PMT except earlier improvements in emotion regulation/social communication. (hawes2023oppositionaldefiantdisorder pages 1-6)
A 2024 RCT in Brazil comparing online vs face-to-face parent training (as add-ons to standard treatment) found: “Parent training was effective in reducing symptoms of ADHD (p = 0.030) and ODD (p = 0.026) irrespective of modality (p = 1.000).” (paiva2024parenttrainingfor pages 1-2)
A 2023 meta-analysis of psychosocial treatments for disruptive behavior disorders in adolescence synthesized RCTs across psychotherapy/training/counseling and delivery formats (group/family/individual/school-linked combined), supporting psychosocial treatment efficacy as a category while emphasizing methodological variation. (boldrini2023systematicreviewand pages 9-12)
Suggested MAXO terms: - Behavioral parent training / parent management training: MAXO:0000217 (behavior therapy) (suggested) - Cognitive behavioral therapy: MAXO:0000127 (cognitive behavioral therapy) (suggested) - Telehealth delivery of behavioral intervention: MAXO:0000753 (telemedicine) (suggested)
No ODD-specific pharmacotherapy standard was established in the retrieved evidence; medication trials largely target comorbid ADHD with ODD outcomes.
Examples from ClinicalTrials.gov: - Atomoxetine trial in ADHD + ODD (COMPLETED; N=181; primary endpoint SNAP-IV Revised ODD subscale at 9 weeks). (NCT00406354 chunk 1) - Clonidine extended-release oral suspension (Onyda XR) Phase IV trial planned for ADHD + ODD with ODD outcomes including Conners 4 ODD scale. (NCT07044609 chunk 1, NCT07044609 chunk 2)
The 2023 Primer emphasizes early- to middle-childhood as the key window when interventions may be most effective and economical and could prevent chronic antisocial trajectories. (hawes2023oppositionaldefiantdisorder pages 36-39, hawes2023oppositionaldefiantdisorder pages 33-36)
Prevention/implementation barriers include limited infrastructure in underserved areas, parental mental health/household adversity affecting engagement, and low mental health literacy (ODD dismissed as “bad behaviour”). (hawes2023oppositionaldefiantdisorder pages 36-39)
Suggested MAXO terms: - Early intervention: MAXO:0000747 (early intervention) (suggested) - Parenting support/education: MAXO:0000208 (patient education) (suggested)
No veterinary/natural disease analogs with explicit taxonomy identifiers were found in the retrieved evidence set; therefore, this section is not available from current sources.
No validated model-organism systems specific to ODD were identified in the retrieved corpus; mechanistic evidence is largely human neuroimaging/psychophysiology and epidemiologic genetics rather than animal models. (hawes2023oppositionaldefiantdisorder pages 12-16, hawes2023oppositionaldefiantdisorder pages 55-59)
Key recent advances in 2023–2024 sources include: 1. High-authority synthesis of ODD across diagnosis, epidemiology, mechanisms, and implementation in Nature Reviews Disease Primers (2023), consolidating prevalence (~3–5%), comorbidity rates, heritability estimates, and identifying key mechanistic hypotheses (emotion-regulation circuitry; punishment sensitivity) and implementation gaps. (hawes2023oppositionaldefiantdisorder pages 1-6, hawes2023oppositionaldefiantdisorder pages 6-9, hawes2023oppositionaldefiantdisorder pages 33-36) 2. Digital/online parent training implementation evidence (2024 RCT) demonstrating online PT can reduce ODD symptoms comparably to face-to-face delivery, supporting scalable service delivery in low-resource contexts. (paiva2024parenttrainingfor pages 1-2) 3. Phenotype stratification for prognosis/treatment response in treatment-seeking youth, where co-occurring conduct problems and anxiety define subgroups with differential executive/emotion-control deficits and outcomes. (halldorsdottir2023cooccurringconductproblems pages 1-2) 4. New/active trials focusing on moderators and comorbid targets, including an RCT explicitly testing emotion regulation as a treatment moderator (NCT06194994) and digital dyadic sleep/insomnia intervention for youth with ODD (NCT06410495). (NCT06194994 chunk 1, NCT06410495 chunk 1)
| Source (first author, year) | Type (review/RCT/cohort/epigenetics/GWAS/registry) | Population | Key findings/statistics | Mechanism highlights | PMID | URL | Publication date/month |
|---|---|---|---|---|---|---|---|
| Hawes, 2023 | Review / Primer | ODD across child/adolescent populations; synthesizes epidemiology, diagnosis, neurobiology, treatment | Population prevalence ~3–5%; lifetime prevalence estimate ~10.2%; male predominance in childhood ~1.6–1.7:1; common co-occurrence: ADHD 28.9%, separation anxiety 20.3%, generalized anxiety 14.9%, depressive disorder 13.9%, CD 11.5%; heritability 0.34–0.73; onset typically before age 8; parenting interventions have strongest support, with brief early-childhood parenting interventions showing large effects and broader disruptive-behavior interventions moderate effects (hawes2023oppositionaldefiantdisorder pages 1-6, hawes2023oppositionaldefiantdisorder pages 6-9, hawes2023oppositionaldefiantdisorder pages 55-59, hawes2023oppositionaldefiantdisorder pages 33-36) | ODD conceptualized in dimensions (angry/irritable, argumentative/defiant, vindictive); coercive parent–child cycles; reduced amygdala/insula/OFC/ACC/striatal responses; altered reward/punishment processing; cortisol hypo-reactivity and autonomic hypoarousal support emotion-regulation and social-cognitive dysfunction models (hawes2023oppositionaldefiantdisorder pages 16-19, hawes2023oppositionaldefiantdisorder pages 12-16, hawes2023oppositionaldefiantdisorder pages 19-22) | Not in text | https://doi.org/10.1038/s41572-023-00441-6 | Jun 2023 |
| Ezpeleta, 2019 | Cohort | Spanish general-population children followed ages 3–9 | Probability of onset increased at age 4 (2.7%) and 5 (4.4%), decreased to age 7 (1.9%), rose again by age 9 (3.6%); cumulative risk of new ODD cases up to age 9 was 21.9%; pooled prevalence cited as 3.6%; early onset linked to higher depression comorbidity, later onset to greater impairment/symptom burden (ezpeleta2019firstincidenceage pages 1-2) | Risk factors for first episode included subthreshold ODD, high irritability/headstrong symptoms, ADHD and other comorbidity, negative affectivity, poor inhibitory/emotional control, punitive parenting, maternal internalizing problems (ezpeleta2019firstincidenceage pages 1-2) | Not in text | https://doi.org/10.1136/bmjopen-2018-022493 | Mar 2019 |
| Helander, 2023 | RCT follow-up | Children with ODD in randomized trial of parent management training (PMT) vs PMT + Coping Power Program | Two-year follow-up: both PMT alone and PMT+CBT reduced disruptive behavior problems and harsh parenting and improved emotion regulation/social communication; combination did not show significant long-term superiority over PMT alone overall (helander2023parentmanagementtraining pages 5-7) | Suggests durable benefit of parenting-focused intervention; emotion-regulation and social-communication skills are modifiable treatment targets (helander2023parentmanagementtraining pages 5-7) | Not in text | https://doi.org/10.1007/s10578-021-01306-3 | Jan 2023 |
| Paiva, 2024 | RCT | Families of children with ADHD and disruptive behavior/ODD symptoms in Brazil; standard treatment vs online PT vs face-to-face PT | ODD comorbidity in ADHD noted as reaching 50% in background; parent training reduced ADHD symptoms (p=0.030) and ODD symptoms (p=0.026) irrespective of online vs face-to-face modality (modality p=1.000); improved physical quality-of-life domains for children (p=0.009) and parents (p=0.050) (paiva2024parenttrainingfor pages 1-2) | Supports scalable digital/online parent-training implementation where access is limited; family environment emphasized as prognostically important (paiva2024parenttrainingfor pages 1-2) | Not in text | https://doi.org/10.3389/fpsyg.2024.1293244 | Feb 2024 |
| Boldrini, 2023 | Systematic review / meta-analysis | 17 RCTs, 1,954 adolescents (61% male), mean age 14.09 years, with ODD/CD/externalizing symptoms | Included psychotherapy, training, counseling, combined psychosocial interventions; designed to meta-analyze change in externalizing symptoms and acceptability across psychosocial treatments in adolescence (boldrini2023systematicreviewand pages 9-12) | Highlights real-world psychosocial treatment formats (group, family, individual, school-linked combined approaches) for adolescent disruptive behavior disorders, including ODD (boldrini2023systematicreviewand pages 9-12) | Not in text | https://doi.org/10.1016/j.jaac.2022.05.002 | May 2023 |
| Halldorsdottir, 2023 | Clinical cohort / treatment-outcome stratification | 134 treatment-seeking youths with ODD (mean age 9.67 years; 36.6% female) | Four profiles identified by anxiety and conduct symptoms; >30% of youths with ODD also meet CD criteria and up to 60% meet anxiety disorder criteria in cited clinical literature; Moderate Anxiety/High Conduct Problems subgroup had more severe behavior, worse emotional self-control/executive functioning, and worse long-term psychosocial treatment outcomes (halldorsdottir2023cooccurringconductproblems pages 1-2) | Supports heterogeneity model of ODD in which co-occurring anxiety and conduct problems mark distinct mechanisms and prognosis (negative emotionality, executive dysfunction) (halldorsdottir2023cooccurringconductproblems pages 1-2) | Not in text | https://doi.org/10.3390/ijerph20043405 | Feb 2023 |
| Aebi, 2016 | GWAS / candidate-gene study | Children/adolescents with ADHD assessed for ODD dimensions/subtypes | ODD heritability estimated around 0.60 in background; no hypothesis-driven association for DRD4, 5-HTTLPR, or OXTR variants; no genome-wide significant loci; inadequate parenting significantly associated with all ODD dimensions, especially defiant/vindictive behavior (aebi2016gene‐setandmultivariate pages 1-2) | Top-ranked genes converged in a protein interaction network centered on beta-catenin signaling and neurite outgrowth, suggesting neurodevelopmental pathway involvement (aebi2016gene‐setandmultivariate pages 1-2) | Not in text | https://doi.org/10.1002/ajmg.b.32346 | Jul 2016 |
| Barker, 2018 | Epigenetics / methylome-wide association | 671 mother–child pairs from epidemiological birth cohort; DNA methylation at birth linked to ODD trajectories ages 7–13 | Methylome-wide significant associations found for ODD and headstrong trajectories, not irritable; ODD worldwide lifetime prevalence quoted as 10%; majority of ODD cases have at least one concurrent psychiatric diagnosis (barker2018amethylomewideassociation pages 1-2) | Biological overlap between ODD/headstrong and ADHD; DNA methylation partly genetically influenced; prenatal maternal anxiety associated with headstrong methylation signatures and cigarette smoking with ODD/headstrong signals (barker2018amethylomewideassociation pages 1-2) | Not in text | https://doi.org/10.1111/cdev.12957 | Sep 2018 |
| Demontis, 2021 | GWAS | ADHD + disruptive behavior disorders (including ODD/CD): 3,802 cases, 31,305 controls, plus Chinese replication | Identified 3 genome-wide significant loci for ADHD+DBDs; chromosome 11 locus rs7118422 replicated across ancestries (P=3.15×10^-10, OR=1.17); SNP-heritability 0.34 for ADHD+DBDs vs 0.20 for ADHD alone; strong genetic correlations with aggression (rg=0.81) and antisocial behavior (rg=0.82) (aebi2016gene‐setandmultivariate pages 1-2) | Indicates ODD/CD comorbidity with ADHD reflects heavier common-variant burden and aggression-related polygenic loading (aebi2016gene‐setandmultivariate pages 1-2) | Not in text | https://doi.org/10.1038/s41467-020-20443-2 | Jan 2021 |
| Deters, 2020 | Neuropsychology / case-control | Youth aged 8–18 with ODD (n=44), CD (n=48, with/without ODD), and healthy controls (n=86) | Visual working memory and inhibitory control impaired in ODD and CD vs controls; anger recognition impaired in ODD; deficits not explained by comorbid ADHD or internalizing symptoms (hawes2023oppositionaldefiantdisorder pages 16-19) | Supports distinct neurocognitive deficits in ODD, especially inhibitory control and anger-recognition dysfunction, independent of ADHD comorbidity (hawes2023oppositionaldefiantdisorder pages 16-19) | Not in text | https://doi.org/10.1080/15622975.2020.1747114 | Apr 2020 |
| Thöne, 2023 | Symptom-level clinical study | 474 German school-age children in ESCAschool ADHD/disruptive behavior cohort (81% male; mean age 8.90 years) | ODD symptom “Argues with Adults” contributed 10% of explained variance in global functional impairment related to ODD/CD/CU symptoms; relationships with adults/children and recreational activities were especially linked to disruptive symptoms (hawes2023oppositionaldefiantdisorder pages 6-9) | Demonstrates that individual ODD symptoms differ in impact on functioning, useful for symptom-prioritized assessment and intervention planning (hawes2023oppositionaldefiantdisorder pages 6-9) | Not in text | https://doi.org/10.1007/s10862-023-10025-z | Mar 2023 |
| NCT06194994, 2024 | Registry / interventional trial | Planned 196 Icelandic-speaking children aged 6–12 with ODD | Recruiting RCT testing whether emotion regulation moderates response to Parent Management Training vs Tuning Your Temper CBT; outcomes include Disruptive Behaviour Rating Scale and K-SADS-PL diagnostic status pre, post, 6 and 18 months (NCT06194994 chunk 1, NCT06194994 chunk 2) | Explicitly tests precision-treatment hypothesis that emotion dysregulation is a mechanistic moderator of ODD treatment response (NCT06194994 chunk 1, NCT06194994 chunk 2) | Not in text | https://clinicaltrials.gov/study/NCT06194994 | Jan 2024 |
| NCT06410495, 2024 | Registry / interventional trial | Children aged 8–17 with prior ODD diagnosis and insomnia plus parents | Recruiting pilot web-based dyadic CBT-I trial (NiteCAPP SINCC); outcomes include daily sleep diary sleep efficiency/onset latency/total sleep time, actigraphy, HRV, and DBD checklist measures (NCT06410495 chunk 1) | Connects sleep dysregulation, parenting stress, and oppositional symptoms in a digital family-based implementation model (NCT06410495 chunk 1) | Not in text | https://clinicaltrials.gov/study/NCT06410495 | May 2024 |
| NCT07044609, 2025 | Registry / phase IV drug trial | Planned children aged 6–12 with ADHD and comorbid ODD | Not-yet-recruiting Phase IV randomized placebo-controlled trial of clonidine ER oral suspension; primary outcome ADHD-RS-5 change; secondary outcomes include Conners 4 ODD scale, CGI, sleep, vitals, ECG, labs, suicidality (NCT07044609 chunk 1, NCT07044609 chunk 2) | Illustrates ongoing pharmacologic implementation focused on ADHD+ODD comorbidity rather than ODD-only monotherapy (NCT07044609 chunk 1, NCT07044609 chunk 2) | Not in text | https://clinicaltrials.gov/study/NCT07044609 | Jul 2025 |
| NCT00406354, 2006 | Registry / phase IV drug trial | 181 children/adolescents aged 6–17 with ADHD and comorbid ODD in Germany | Completed 3-arm randomized double-blind placebo-controlled atomoxetine trial; primary endpoint SNAP-IV Revised ODD subscale at 9 weeks, with ADHD and family-impact secondary measures (NCT00406354 chunk 1) | Represents real-world psychopharmacology for ADHD+ODD comorbidity using ADHD-directed medication and ODD symptom outcomes (NCT00406354 chunk 1) | Not in text | https://clinicaltrials.gov/study/NCT00406354 | Nov 2006 |
Table: This table summarizes the most important citable sources retrieved in the session on Oppositional Defiant Disorder, spanning reviews, cohorts, RCTs, molecular studies, and active clinical trials. It highlights the strongest recent evidence on epidemiology, mechanisms, and treatment implementation for rapid use in the final report.
References
(hawes2023oppositionaldefiantdisorder pages 1-6): David J. Hawes, Frances Gardner, Mark R. Dadds, Paul J. Frick, Eva R. Kimonis, Jeffrey D. Burke, and Graeme Fairchild. Oppositional defiant disorder. Nature Reviews Disease Primers, 9:1-17, Jun 2023. URL: https://doi.org/10.1038/s41572-023-00441-6, doi:10.1038/s41572-023-00441-6. This article has 98 citations.
(hawes2023oppositionaldefiantdisorder pages 55-59): David J. Hawes, Frances Gardner, Mark R. Dadds, Paul J. Frick, Eva R. Kimonis, Jeffrey D. Burke, and Graeme Fairchild. Oppositional defiant disorder. Nature Reviews Disease Primers, 9:1-17, Jun 2023. URL: https://doi.org/10.1038/s41572-023-00441-6, doi:10.1038/s41572-023-00441-6. This article has 98 citations.
(hawes2023oppositionaldefiantdisorder pages 16-19): David J. Hawes, Frances Gardner, Mark R. Dadds, Paul J. Frick, Eva R. Kimonis, Jeffrey D. Burke, and Graeme Fairchild. Oppositional defiant disorder. Nature Reviews Disease Primers, 9:1-17, Jun 2023. URL: https://doi.org/10.1038/s41572-023-00441-6, doi:10.1038/s41572-023-00441-6. This article has 98 citations.
(balia2020…behaviourin pages 26-29): C Balia. … behaviour in children and adolescents with conduct disorder or oppositional defiant disorder: neuropsychological characterization and drug treatments. preliminary …. Unknown journal, 2020.
(hawes2023oppositionaldefiantdisorder pages 19-22): David J. Hawes, Frances Gardner, Mark R. Dadds, Paul J. Frick, Eva R. Kimonis, Jeffrey D. Burke, and Graeme Fairchild. Oppositional defiant disorder. Nature Reviews Disease Primers, 9:1-17, Jun 2023. URL: https://doi.org/10.1038/s41572-023-00441-6, doi:10.1038/s41572-023-00441-6. This article has 98 citations.
(NCT06410495 chunk 1): Melanie Stearns. Digital Dyadic Family Based Intervention to Improve Sleep in Children with ODD and Their Parents: NiteCAPP SINCC (Pilot). University of South Florida. 2024. ClinicalTrials.gov Identifier: NCT06410495
(NCT06194994 chunk 1): Urdur Njardvik. Emotion Regulation as a Moderator of Two Different Treatments for Children With ODD. University of Iceland. 2024. ClinicalTrials.gov Identifier: NCT06194994
(boldrini2023systematicreviewand pages 9-12): Tommaso Boldrini, Viola Ghiandoni, Elisa Mancinelli, Silvia Salcuni, and Marco Solmi. Systematic review and meta-analysis: psychosocial treatments for disruptive behavior symptoms and disorders in adolescence. Journal of the American Academy of Child and Adolescent Psychiatry, May 2023. URL: https://doi.org/10.1016/j.jaac.2022.05.002, doi:10.1016/j.jaac.2022.05.002. This article has 17 citations and is from a highest quality peer-reviewed journal.
(ezpeleta2019firstincidenceage pages 1-2): Lourdes Ezpeleta, J Blas Navarro, Nuria de la Osa, Eva Penelo, and Josep Maria Domènech. First incidence, age of onset outcomes and risk factors of onset of dsm-5 oppositional defiant disorder: a cohort study of spanish children from ages 3 to 9. BMJ Open, 9:e022493, Mar 2019. URL: https://doi.org/10.1136/bmjopen-2018-022493, doi:10.1136/bmjopen-2018-022493. This article has 29 citations and is from a peer-reviewed journal.
(barker2018amethylomewideassociation pages 1-2): Edward D Barker, Esther Walton, Charlotte A M Cecil, Richard Rowe, Sara R Jaffee, Barbara Maughan, Thomas G O'Connor, Argyris Stringaris, Alan J Meehan, Wendy McArdle, Caroline L Relton, and Tom R Gaunt. A methylome-wide association study of trajectories of oppositional defiant behaviors and biological overlap with attention deficit hyperactivity disorder. Child Development, 89:1839-1855, Sep 2018. URL: https://doi.org/10.1111/cdev.12957, doi:10.1111/cdev.12957. This article has 34 citations and is from a highest quality peer-reviewed journal.
(hawes2023oppositionaldefiantdisorder pages 6-9): David J. Hawes, Frances Gardner, Mark R. Dadds, Paul J. Frick, Eva R. Kimonis, Jeffrey D. Burke, and Graeme Fairchild. Oppositional defiant disorder. Nature Reviews Disease Primers, 9:1-17, Jun 2023. URL: https://doi.org/10.1038/s41572-023-00441-6, doi:10.1038/s41572-023-00441-6. This article has 98 citations.
(aebi2016gene‐setandmultivariate pages 1-2): Marcel Aebi, Marjolein M. J. van Donkelaar, Geert Poelmans, Jan K. Buitelaar, Edmund J. S. Sonuga‐Barke, Argyris Stringaris, IMAGE consortium, Stephen V. Faraone, Barbara Franke, Hans‐Christoph Steinhausen, and Kimm J. E. van Hulzen. Gene‐set and multivariate genome‐wide association analysis of oppositional defiant behavior subtypes in attention‐deficit/hyperactivity disorder. American Journal of Medical Genetics, 171:573-588, Jul 2016. URL: https://doi.org/10.1002/ajmg.b.32346, doi:10.1002/ajmg.b.32346. This article has 61 citations.
(hawes2023oppositionaldefiantdisorder pages 33-36): David J. Hawes, Frances Gardner, Mark R. Dadds, Paul J. Frick, Eva R. Kimonis, Jeffrey D. Burke, and Graeme Fairchild. Oppositional defiant disorder. Nature Reviews Disease Primers, 9:1-17, Jun 2023. URL: https://doi.org/10.1038/s41572-023-00441-6, doi:10.1038/s41572-023-00441-6. This article has 98 citations.
(hawes2023oppositionaldefiantdisorder pages 12-16): David J. Hawes, Frances Gardner, Mark R. Dadds, Paul J. Frick, Eva R. Kimonis, Jeffrey D. Burke, and Graeme Fairchild. Oppositional defiant disorder. Nature Reviews Disease Primers, 9:1-17, Jun 2023. URL: https://doi.org/10.1038/s41572-023-00441-6, doi:10.1038/s41572-023-00441-6. This article has 98 citations.
(ezpeleta2019firstincidenceage pages 6-7): Lourdes Ezpeleta, J Blas Navarro, Nuria de la Osa, Eva Penelo, and Josep Maria Domènech. First incidence, age of onset outcomes and risk factors of onset of dsm-5 oppositional defiant disorder: a cohort study of spanish children from ages 3 to 9. BMJ Open, 9:e022493, Mar 2019. URL: https://doi.org/10.1136/bmjopen-2018-022493, doi:10.1136/bmjopen-2018-022493. This article has 29 citations and is from a peer-reviewed journal.
(halldorsdottir2023cooccurringconductproblems pages 1-2): Thorhildur Halldorsdottir, Maria G Fraire, Deborah A. G. Drabick, and Thomas H. Ollendick. Co-occurring conduct problems and anxiety: implications for the functioning and treatment of youth with oppositional defiant disorder. International Journal of Environmental Research and Public Health, 20:3405, Feb 2023. URL: https://doi.org/10.3390/ijerph20043405, doi:10.3390/ijerph20043405. This article has 11 citations.
(paiva2024parenttrainingfor pages 1-2): Gabrielle Chequer de Castro Paiva, Jonas Jardim de Paula, Danielle de Souza Costa, Antônio Alvim-Soares, Daniel Augusto Ferreira e Santos, Julia Silva Jales, Marco Aurélio Romano-Silva, and Débora Marques de Miranda. Parent training for disruptive behavior symptoms in attention deficit hyperactivity disorder: a randomized clinical trial. Frontiers in Psychology, Feb 2024. URL: https://doi.org/10.3389/fpsyg.2024.1293244, doi:10.3389/fpsyg.2024.1293244. This article has 22 citations and is from a peer-reviewed journal.
(NCT00406354 chunk 1): Comparison of Atomoxetine Versus Placebo in Children and Adolescents With ADHD and Comorbid ODD in Germany. Eli Lilly and Company. 2006. ClinicalTrials.gov Identifier: NCT00406354
(NCT07044609 chunk 1): A Study to Assess the Effectiveness and Safety of Clonidine Extended-Release OnydaTM XR in Children With ADHD and ODD. Las Vegas Medical Research, LLC DBA Vector Clinical Trials. 2025. ClinicalTrials.gov Identifier: NCT07044609
(NCT07044609 chunk 2): A Study to Assess the Effectiveness and Safety of Clonidine Extended-Release OnydaTM XR in Children With ADHD and ODD. Las Vegas Medical Research, LLC DBA Vector Clinical Trials. 2025. ClinicalTrials.gov Identifier: NCT07044609
(hawes2023oppositionaldefiantdisorder pages 36-39): David J. Hawes, Frances Gardner, Mark R. Dadds, Paul J. Frick, Eva R. Kimonis, Jeffrey D. Burke, and Graeme Fairchild. Oppositional defiant disorder. Nature Reviews Disease Primers, 9:1-17, Jun 2023. URL: https://doi.org/10.1038/s41572-023-00441-6, doi:10.1038/s41572-023-00441-6. This article has 98 citations.
(helander2023parentmanagementtraining pages 5-7): Maria Helander, Pia Enebrink, Clara Hellner, and Johan Ahlen. Parent management training combined with group-cbt compared to parent management training only for oppositional defiant disorder symptoms: 2-year follow-up of a randomized controlled trial. Child Psychiatry and Human Development, 54:1112-1126, Jan 2023. URL: https://doi.org/10.1007/s10578-021-01306-3, doi:10.1007/s10578-021-01306-3. This article has 22 citations and is from a peer-reviewed journal.
(NCT06194994 chunk 2): Urdur Njardvik. Emotion Regulation as a Moderator of Two Different Treatments for Children With ODD. University of Iceland. 2024. ClinicalTrials.gov Identifier: NCT06194994